Theranostics company to test heparin monitor:
This article was originally published in Clinica
Executive Summary
PharmaNetics, a Raleigh, North Carolina-based developer of theranostics, has begun clinical testing of a rapid test to monitor the anticoagulant effects of low molecular weight heparin. The Phase I study is to establish the performance of the test card in patients receiving the treatment for arterial or venous thrombosis when optimised, the test will be included in additional clinical trials designed to collect data for a 510(k) US marketing clearance submission later this year, said the company.